CD19 and acute lymphoblastic leukemia: Although several target antigens, including CD20 [78], ROR1 [79], CD23 [80], and κ-light chain [81], were studied in CLL, the most promising clinical data, similar to ALL, was obtained using CD19-CAR T-cells [82].